Standard of Care Treatment + Standard lymphodepletion regimen + KYV-101
Phase 2/3Recruiting 0 watching 0 views this week⚡ Active
57
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myasthenia Gravis
Conditions
Myasthenia Gravis, Generalized Myasthenia Gravis
Trial Timeline
Aug 28, 2024 → Sep 1, 2028
NCT ID
NCT06193889About Standard of Care Treatment + Standard lymphodepletion regimen + KYV-101
Standard of Care Treatment + Standard lymphodepletion regimen + KYV-101 is a phase 2/3 stage product being developed by Kyverna Therapeutics for Myasthenia Gravis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06193889. Target conditions include Myasthenia Gravis, Generalized Myasthenia Gravis.
Hype Score Breakdown
Clinical
22
Activity
15
Company
2
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06193889 | Phase 2/3 | Recruiting |
Competing Products
20 competing products in Myasthenia Gravis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| tacrolimus | Astellas Pharma | Phase 3 | 77 |
| Tacrolimus capsule + Placebo | Astellas Pharma | Phase 3 | 77 |
| tacrolimus + placebo | Astellas Pharma | Phase 3 | 77 |
| Ravulizumab | AstraZeneca | Pre-clinical | 23 |
| Cladribine Low Dose + Cladribine High Dose | Merck | Phase 3 | 77 |
| Remibrutinib (Blinded) + Remibrutinib (Open Label) | Novartis | Phase 3 | 77 |
| Placebo + CFZ533 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Phase 3 | 77 |
| mycophenolate mofetil [CellCept] + Placebo | Roche | Phase 3 | 77 |
| mycophenolate mofetil (CellCept) + placebo | Roche | Phase 3 | 77 |
| inebilizumab + IV Placebo | Amgen | Phase 3 | 76 |
| Inebilizumab | Amgen | Phase 2 | 51 |
| Abatacept Injection | Bristol Myers Squibb | Phase 1 | 32 |
| Tolebrutininb + Placebo | Sanofi | Phase 3 | 76 |
| Pozelimab + Cemdisiran + Cemdisiran + Pozelimab | Regeneron Pharmaceuticals | Phase 3 | 76 |
| HIZENTRA ® | CSL | Phase 2 | 51 |
| Subcutaneous immunoglobulins | CSL | Phase 1 | 32 |
| Human normal immunoglobulin G (IgG) | CSL | Phase 3 | 76 |
| zilucoplan (RA101495) | UCB | Phase 3 | 74 |
Other Products from Kyverna Therapeutics
Standard lymphodepletion regimenPhase 2
44
KYV-101 + Standard lymphodepletion regimen + Anti-CD20 mABPhase 2
44
KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapyPhase 1/2
33
KYV-101 anti-CD19 CAR-T cell therapy + Standard lymphodepletion regimenPhase 1/2
33
KYV-101 + Standard lymphodepletion regimenPhase 1/2
33